Patent: 7,611,702
✉ Email this page to a colleague
Summary for Patent: 7,611,702
Title: | TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy |
Abstract: | The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy. |
Inventor(s): | Fischkoff; Steven (Short Hills, NJ), Lowy; Israel (Dobbs Ferry, NY), Yellin; Michael (Montclair, NJ), Yang; James Chung-Yin (Silver Spring, MD) |
Assignee: | Medarex, Inc. (Princeton, NJ) |
Application Number: | 11/557,835 |
Patent Claims: | see list of patent claims |
Details for Patent 7,611,702
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2025-11-08 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2025-11-08 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2025-11-08 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2025-11-08 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2025-11-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |